

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

November 14, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2017

INNOVUS PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

|  |                             |                                   |
|--|-----------------------------|-----------------------------------|
| Nevada   | 000-52991                   | 90-0814124                        |
| (State or other jurisdiction of incorporation) | (Commission<br>File Number) | (IRS Employer Identification No.) |

|  |            |
|--|------------|
| 8845 Rehco Road, San Diego, CA           | 92122      |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (858) 964-5123

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 8.01 – Other Events

On November 14, 2017, the Company issued a press release reporting the launch of our FlutiCare™ OTC Nasal Spray Allergy Relief product in the U.S. FlutiCare™ was approved by the U.S. Food and Drug Administration for OTC sale through our partner’s approved abbreviated new drug application No. 207957. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

| Exhibit Number | Description   |
|----------------|---|
| <u>99.1</u>    | Press release issued November 14, 2017, reporting the launch of FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. |



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOVUS  
PHARMACEUTICALS,  
INC.

Date: November 14, 2017 By: /S/ Bassam Damaj  
Bassam Damaj, CEO



EXHIBIT INDEX

| Exhibit<br>Number | Description   |
|-------------------|---|
| <u>99.1</u>       | Press release issued November 14, 2017, reporting the launch of FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. |